INTELLIA THERAPEUTICS INC. - COMMON STOCK

Intellia Therapeutics Names James Basta, J.D., as Executive Vice President, General Counsel and Corporate Secretary

24 Jun 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

04 Jun 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces First Quarter 2021 Financial Results

06 May 2021 06:30:01 By Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2021 Earnings and Company Updates

29 Apr 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting

27 Apr 2021 15:35:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors

12 Apr 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis

30 Mar 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors

25 Mar 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium

10 Mar 2021 06:30:00 By Nasdaq GlobeNewswire

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results

25 Feb 2021 06:30:00 By Nasdaq GlobeNewswire